Oorsprong van het eerstegraads netwerk van Ben Machielse
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.
6
| Subsidiary | Biotechnology | 6 |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Ben Machielse via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GENOCEA BIOSCIENCES, INC. | Biotechnology | Corporate Officer/Principal Private Equity Investor | |
TRANSLATE BIO, INC. | Biotechnology | Director/Board Member | |
SYNCONA LIMITED | Investment Trusts/Mutual Funds | Director/Board Member Private Equity Investor | |
University of Pennsylvania | College/University | Doctorate Degree Doctorate Degree | |
University of Maryland | College/University | Undergraduate Degree | |
Aveni SA
Aveni SA Chemicals: Major DiversifiedProcess Industries Aveni SA designs, develops, manufactures and markets chemical formulations. It enables future technologies with its approach to metallization for semiconductor, MEMS, advanced packaging, and flex applications. The company was founded in 2001 and is headquartered in Massy, France. | Chemicals: Major Diversified | Director/Board Member | |
SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Leiden | College/University | Graduate Degree | |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
Canbex Therapeutics Ltd.
Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
INKEF Capital BV
INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor | |
Alexion Pharma GmbH | Corporate Officer/Principal | ||
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Medical Distributors | Founder Director/Board Member Chief Executive Officer | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Chairman | |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
The Fuqua School of Business | College/University | Masters Business Admin | |
Aalto University School of Business | College/University | Masters Business Admin | |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member | |
University of Wisconsin Superior | College/University | Undergraduate Degree | |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member | |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Salvia BioElectronics BV
Salvia BioElectronics BV BiotechnologyHealth Technology Salvia BioElectronics BV develops a bioelectronics therapy for people suffering from chronic neurological diseases. The company was founded by Sjaak Deckers and Hubert Martens in 2017 and is headquartered in Eindhoven, the Netherlands. | Biotechnology | Director/Board Member | |
ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
Merrimack Ales LLC
Merrimack Ales LLC Beverages: AlcoholicConsumer Non-Durables Merrimack Ales LLC is engaged in brewery production. It includes perennials, seasonal, and hypothesis beer. The company was founded by Adam Pearson in 2014 and is headquartered in Lowell, MA. | Beverages: Alcoholic | Consultant / Advisor | |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Trex Bio, Inc.
Trex Bio, Inc. Pharmaceuticals: MajorHealth Technology Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Chief Executive Officer | |
TRex Bio Ltd.
TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Biotechnology | Director/Board Member | |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member | |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 25 |
Verenigd Koninkrijk | 8 |
Nederland | 8 |
Zwitserland | 7 |
Frankrijk | 3 |
Sectoraal
Health Technology | 30 |
Consumer Services | 7 |
Commercial Services | 6 |
Finance | 5 |
Miscellaneous | 2 |
Operationeel
Director/Board Member | 66 |
Corporate Officer/Principal | 22 |
Chief Executive Officer | 15 |
President | 14 |
Founder | 12 |
Sterkste connecties
Insiders | |
---|---|
Roel Bulthuis | 29 |
Sara Nayeem | 23 |
Cristina Csimma | 21 |
Peter van Vlasselaer | 15 |
James McArthur | 15 |
Ravichandran Rao | 10 |
Jason Meyenburg | 9 |
Art Taveras | 7 |
David de Graaf | 6 |
Ravichandran Venkataramani | 4 |
Anthony Walsh | 1 |
- Beurs
- Insiders
- Ben Machielse
- Bedrijfsconnecties